Evidence map›Paper›PMID 39827146›Full record

ArticleGut pathogens2025

Metagenomics: a new frontier for routine pathology testing of gastrointestinal pathogens.

Nicola Z Angel, Mitchell J Sullivan, Areej Alsheikh-Hussain, Liang Fang, Samantha MacDonald, Alena Pribyl, Blake Wills, Gene W Tyson, Philip Hugenholtz, Donovan H Parks and 2 more

Abstract read
In one paragraph

Article in Gut pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. A Pilot Study ofDiagnostics (Basel, Switzerland) · 2026
    Article
  4. Specialty grand challenge in gastrointestinal infections.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nicola Z AngelMicroba Pty Ltd, Brisbane, Australia. nicola.angel@microba.com.
Mitchell J SullivanMicroba Pty Ltd, Brisbane, Australia.
Areej Alsheikh-HussainMicroba Pty Ltd, Brisbane, Australia.
Liang FangMicroba Pty Ltd, Brisbane, Australia.
Samantha MacDonaldMicroba Pty Ltd, Brisbane, Australia.
Alena PribylMicroba Pty Ltd, Brisbane, Australia.
Blake WillsMicroba Pty Ltd, Brisbane, Australia.
Gene W TysonMicroba Pty Ltd, Brisbane, Australia.
Philip HugenholtzMicroba Pty Ltd, Brisbane, Australia.
Donovan H ParksMicroba Pty Ltd, Brisbane, Australia.
Paul GriffinMicroba Pty Ltd, Brisbane, Australia.
David L A WoodMicroba Pty Ltd, Brisbane, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccurate and comprehensive identification of enteropathogens, causing infectious gastroenteritis, is essential for optimal patient treatment and effective isolation processes in health care systems. Traditional diagnostic techniques are well established and optimised in low-cost formats. However, thorough testing for a wider range of causal agents is time consuming and remains limited to a subset of pathogenic organisms. Metagenomic next-generation sequencing (mNGS) allows the identification of all pathogens in a sample in a single test, without a reliance on culture or introduction of target selection bias. This study aims to determine the ability to routinely apply mNGS testing, in comparison to traditional culture or polymerase chain reaction (PCR) based tests, for the identification of causal pathogens for gastrointestinal infections.

resultsThe performance of mNGS, PCR and microscopy, culture and sensitivity (MCS) assays was established using 2,619 prospectively collected faecal samples from patients with symptomology indicative of infectious gastroenteritiss. Commonly experienced pathogens including Aeromonas spp, Campylobacter spp, Salmonella spp and Giardia spp, in single and co-infected patients, were used to establish test outcomes. When testing for these organisms, using the combined result from either or both PCR and MCS testing as the comparator, the mNGS assay had clinically acceptable sensitivity (89.2-100%). Further, the mNGS assay detected 14 additional enteropathogens, that were either not detected or not tested, by initial PCR/MCS testing.

conclusionsThe advantage of mNGS compared to other syndromic testing systems is the broad range of detectable targets and the ability to interrogate samples without clinician informed or assay specific bias. With the development of newer sequencing assays, it is now feasible to test for a wide range of target organisms in a sample using a single mNGS test. Overall, the mNGS based approach enabled pathogen detection that was comparable to conventional diagnostics and was shown to have the potential to be extended for the detection of many pathogens and genes of clinical interest. In conclusion, the mNGS assay offers an easy, sample to answer workflow with rapid detection of enteropathogens and has the potential to improve diagnosis, therapy and infection control precautions.

Indexed as

EnteropathogensFaecalGastrointestinalInfectionMetagenomicsPathogen

Identifiers

PMID39827146
PMCPMC11742996

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.